 SEATTLE, Feb. 02, 2021 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq:ATOS, a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces that based on substantially positive results achieved with the patients enrolled to date in its Australian open-label Phase 2 clinical study of oral Endoxifen administered in the window of opportunity between diagnosis of breast cancer and surgery, Atossa has halted the study and is accelerating its Endoxifen program in the United States. 